HEALTH

Schiff appoints Glenn Schaeffer to board of directors

BY Michael Johnsen

SALT LAKE CITY Schiff Nutrition on Friday announced the appointment of Glenn Schaeffer, 54, to its board of directors effective Dec. 1.

“Glenn has a long-standing interest in our business, having previously served on the board of the company from 1997 to 2000, and we are delighted to welcome him back to the Schiff Nutrition International board,” stated Schiff chairman Eric Weider.

“Glenn’s extensive financial and operational experience in building world famous hotel and gaming brands, and in leading large business enterprises will be a tremendous asset for Schiff as we continue to focus on our long term goal of profitable branded growth,” added Bruce Wood, Schiff president and chief executive officer.

Schaeffer is co-founder, president and chief executive officer at Fontainebleau Resorts, headquartered in Las Vegas. Fontainebleau Resorts owns the historic Fontainebleau Miami Beach and is building the Fontainebleau Las Vegas, a luxury casino hotel expected to open in late 2009. Schaeffer also served as president and chief financial officer of Mandalay Resort Group, a leading company in the gaming industry, until its sale to MGM-Mirage in April 2005. During his 22-year tenure at Mandalay, formerly Circus Circus Enterprises, Schaeffer set an industry record for financing new projects.

Schaeffer also founded the Black Mountain Institute, a humanities and social issues think tank, at the University of Nevada at Las Vegas.

With the addition of Schaeffer, Schiff’s board has eight members.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Jason Ash named PacificHealth president and CEO

BY Michael Johnsen

MATAWAN, N.J. PacificHealth Laboratories on Thursday named Jason Ash as the company’s president and chief operating officer, as well as a member of the company’s board, effective Jan. 3.

Ash assumes the role of president from Portman, who will continue to serve as chief executive officer, chief scientific officer and chairman.

“Jason brings a great deal of knowledge and experience in the performance beverage arena, and actually led Cadbury’s negotiations leading to their acquisition of the Accelerade and Endurox trade marks and intellectual property,” Portman stated. “Jason’s existing knowledge of our company and our growth objectives will enable him to hit the ground running and provides an excellent opportunity for PacificHealth to rapidly expand upon our existing growth strategy.”

Ash also assumes chief operating officer duties currently held by Stephen Kuchen, who will continue to serve as chief financial officer, treasurer, secretary and director.

Ash brings a decade worth of experience in commercial brand management and consumer marketing to PacificHealth, most recently serving as general manager and vice president of Cadbury Schweppes Americas Beverages Sports in the energy and water category unit.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Next announces results of Nexrutine dietary supplement study

BY Michael Johnsen

SALINAS, Calif. Next Pharmaceuticals announced Thursday the results of a clinical study on Nexrutine, conducted at The LaValle Metabolic Institute in Cincinnati.

The study concluded that Nexrutine, when used as a dietary supplement, helps in the management of pain and/or inflammation and helps promote a restful sleep with minimal side effects.

“Suffering from pain and inflammation can be a life-changing challenge,” stated Jim LaValle, founder of The LaValle Metabolic Institute and author of many books, including Cracking the Metabolic Code and the Cox-2 Connection. “Many of our patients are relieved to find a natural remedy that is not only cardio protective, but unlike aspirin, is easy on the stomach. This study demonstrates that Nexrutine has an excellent safety profile.”

Out of the 401 participants in the study, 92 percent reported Nexrutine provided pain relief and 93 percent reported improvement in their overall condition.

Nexrutine is a proprietary blend of natural ingredients developed to address general aches and pains associated with physical activity and over-exertion.

The clinical trial was designed to be an open label, single center, clinical trial.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?